智通财经APP获悉，香港联交所最新资料显示，10月14日，华昊中天医药-B(02563)股东将股票存入华泰 香港，存仓市值1.25亿港元，占比7.91%。 华昊中天医药-B发布截至2025年6月30日止六个月中期业绩，营业收入1478.7万元(人民币，下同)，同比 减少55.36%；净亏损5404.1万元，同比收窄23.41%；基本每股亏损0.15元。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京華昊中天生物醫藥股份有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02563 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 216,720,857 | RMB | | | 1 RMB | | 216,720,857 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 216,720,857 | RMB | | | 1 RMB | | 216,720,857 | | 2. 股份分類 | 普 ...

Financial Performance - Revenue for the six months ended June 30, 2025, was RMB 14,787,000, a decrease of 55.4% compared to RMB 33,123,000 in 2024[9]. - Gross profit for the same period was RMB 13,747,000, down 51.5% from RMB 28,330,000 in 2024[9]. - Net loss for the six months was RMB 54,041,000, a reduction of 23.4% compared to RMB 70,560,000 in 2024[9]. - The company's revenue for the reporting period was RMB 148 million, a decrease of 55.4% compared to RMB 331 million for the six months ended June 30, 2024, primarily due to fluctuations in sales volume from the product "Ulitide Long Injection" following a strategic adjustment[58]. - Total operating revenue for the first half of 2025 was RMB 14,787 thousand, a decrease of 55.5% compared to RMB 33,123 thousand in the same period of 2024[113]. - Net loss for the first half of 2025 was RMB 54,041 thousand, an improvement from a net loss of RMB 70,560 thousand in the same period of 2024, representing a reduction of 23.4%[114]. - Basic earnings per share for the first half of 2025 was RMB (0.15), an improvement from RMB (0.20) in the same period of 2024[114]. Research and Development - Research and development expenses amounted to RMB 41,343,000, a decrease of 24.3% from RMB 54,645,000 in 2024[9]. - The company has one commercialized product and 19 items in its research and development pipeline as of the report date[10]. - The core product, Youtidelong injection, was approved by the National Medical Products Administration in 2021 for treating recurrent or metastatic breast cancer[10]. - Clinical trials for new indications of Youtidelong are progressing well, including two Phase III registration studies for non-small cell lung cancer and breast cancer[11]. - The company is expanding its research pipeline, including a Phase II clinical study for first-line treatment of advanced pancreatic cancer[11]. - The company is advancing the development of UTD capsules with ongoing Phase II/III clinical trials for triple-negative breast cancer, advanced gastric cancer, and advanced ovarian cancer[13]. - The company has received IND approval for the Phase II-III trial of UTD capsules in advanced gastric cancer and ovarian cancer, with patient recruitment ongoing[13]. - The ongoing clinical trials reflect the company's commitment to expanding treatment options for patients with difficult-to-treat cancers[31]. Clinical Trials and Product Development - The Phase III trial for UTD injection in HER2-negative breast cancer has enrolled 2/3 of the target patients, with a low incidence of adverse events, indicating good safety[14]. - In the Phase II trial for advanced NSCLC, the overall response rate (ORR) was 19.0% and the disease control rate (DCR) was 81.0%, with a median progression-free survival (PFS) of 4.4 months[15]. - The ongoing Phase III trial for UTD injection in advanced NSCLC has completed approximately 40% of patient enrollment, with manageable adverse events reported[19]. - In the Phase II trial for advanced gastric and esophageal cancer, the combination of UTD with PD-1 inhibitors showed an ORR of 65.2% and a complete response rate (CBR) of 100% in the gastric cancer cohort[19]. - The safety profile of UTD injection in various trials has been favorable, with no treatment-related deaths reported[19]. - The clinical trial of UTD1 combined with bevacizumab for HER2-negative breast cancer brain metastases showed a CNS-ORR of 42.6% and a median PFS of 7.7 months[26]. - The trial for UTD1 combined with capecitabine for breast cancer brain metastases has commenced in the U.S., marking a significant step in the company's international strategy[31]. - The ongoing IIT trial for Uterodalon capsules combined with Capecitabine in advanced breast cancer has shown an ORR of over 54.8% and a CBR of 83.9%[37]. Financial Position and Cash Flow - Cash and cash equivalents as of June 30, 2025, were RMB 468,565,000, a slight increase of 0.4% from RMB 466,636,000 at the end of 2024[9]. - The current ratio improved to 9.8 as of June 30, 2025, compared to 8.8 as of December 31, 2024, indicating better short-term financial stability[70]. - The net value of current assets decreased by 6.8% to RMB 578.1 million as of June 30, 2025, from RMB 620.1 million as of December 31, 2024, due to funding for R&D activities and facility construction[72]. - The company's cash and cash equivalents, along with financial assets, totaled RMB 569.4 million as of June 30, 2025, a decrease of 6.3% from RMB 607.6 million as of December 31, 2024[74]. - Cash inflows from operating activities for the first half of 2025 were RMB 23,955 thousand, down from RMB 38,501 thousand in 2024, representing a decrease of approximately 37.8%[119]. - Cash outflows from operating activities increased to RMB 123,163 thousand in 2025 from RMB 107,963 thousand in 2024, marking an increase of about 14.1%[120]. - The ending cash and cash equivalents balance as of June 30, 2025, was RMB 457,288 thousand, compared to RMB 375,370 thousand at the end of June 2024, indicating an increase of approximately 21.8%[120]. Shareholder Information and Corporate Governance - Tang Li holds a total of 45,304,515 shares, representing 15.86% of the company's total equity, as of June 30, 2025[82]. - Qiu Rongguo also holds 45,304,515 shares, equivalent to 15.86% of the company's total equity, as of June 30, 2025[82]. - Major shareholders include Tang Li and Qiu Rongguo, each with 29.47% and 15.86% of the non-listed shares, respectively[84]. - The company has implemented employee incentive plans in November 2020, January 2021, and January 2022 to recognize and motivate employee contributions[79]. - The company has adopted the corporate governance code of the Hong Kong Stock Exchange as its governance standard[97]. - The board of directors has resolved not to recommend any interim dividend for the six months ended June 30, 2025, consistent with the previous period[102]. Regulatory and Compliance - The company’s financial statements are prepared in accordance with the Chinese Accounting Standards and relevant regulations[128]. - The statutory tax rate for the company's subsidiaries in China is 25%, with a preferential rate of 15% applied during the reporting period[146]. - The company obtained a high-tech enterprise certificate on October 29, 2024, allowing it to enjoy a 15% corporate income tax rate for three years[148]. - The audit committee has reviewed the interim financial statements for the reporting period and confirmed compliance with applicable accounting standards and regulations[104]. - The company plans to enhance communication with compliance advisors to ensure adherence to listing rules and regulations[95].

呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02563 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 216,720,857 | RMB | | 1 | RMB | | 216,720,857 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 216,720,857 | RMB | | 1 | RMB | | 216,720,857 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京華昊中天生物醫藥股份有限公司 | 2. 股份分類 | 普通 ...

华昊中天医药-B(02563)发布截至2025年6月30日止六个月中期业绩，营业收入1478.7万元(人民币，下 同)，同比减少55.36%;净亏损5404.1万元，同比收窄23.41%;基本每股亏损0.15元。 ...

Core Insights - The company reported a significant decline in revenue for the six months ending June 30, 2025, with total revenue of 14.787 million RMB, representing a year-on-year decrease of 55.36% [1] - The net loss for the period was 54.041 million RMB, which is a reduction of 23.41% compared to the previous year [1] - The basic loss per share was reported at 0.15 RMB [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失 承擔任何責任。 Beijing Biostar Pharmaceuticals Co., Ltd. 北 京 華 昊 中 天 生 物 醫 藥 股 份 有 限 公 司 於中華人民共和國註冊成立的股份有限公司） （股份代號：2563） 中期業績公告 截至2025年6月30日止六個月 北京華昊中天生物醫藥股份有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然公佈本公 司及其附屬公司（ 統稱「本集團」）截至2025年6月30 日止六個月的未經審計綜合中期業績連 同2024年同期的比較數字。該等中期業績並未經核數師審計或審閱，惟已由本公司審計委 員會審閱。 在本公告內，「我們」及「我們的」均指本公司，如文義另有所指，則指本集團。本公告所載 若 干 金 額 及 百 分 比 數 字 已 約 整 或 已 四 捨 五 入 至 小 數 點 後 一 位 或 兩 位 數（ 如 適 用 ）。 任 何 表 格、圖表或其他地方所示總額與所列數額 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失 承擔任何責任。 （股份代號：2563） 於2025年8月25日舉行的股東週年大會 投票表決結果 茲提 述北 京華 昊中 天生 物醫 藥股 份有 限公 司（「 本公 司」）日期 均為 2025 年 7 月25 日的 股東 週 年大會通告（「股東週年大會通告」）及通函（「通函」）。除另有指明者外，本公告所用詞彙與 通函所界定者具有相同涵義。 股東週年大會投票表決結果 董 事 會 欣 然 宣 佈 ，於 2025 年 8 月 25 日 舉行 的 股 東 週 年 大 會 上 ， 股 東 週 年大 會 通 告 內 載 列 的 所有普通決議案（「普通決議案」）及一項特別決議案（「特別決議案」，連同普通決議案統稱為 「 該 等 決 議 案」）已 獲 股 東 以 投 票 方 式 正式 通 過 。 於 股 東 週 年 大 會 上 通 過 的 該 等 決 議 案 的 投 票表決結果如下： | | | | | | | | | | | | | | ...

於中華人民共和國註冊成立的股份有限公司） （股份代號：2563） 有關核數師辭任之 補充公告 茲提 述北 京華 昊中 天生 物醫 藥股 份有 限公 司（「 本公 司」）日期 為2025 年7 月 24 日 內容 有關 核 數師辭任的公告（「該公告」）。除另行界定外，本公告所用詞彙與該公告所界定者具有相同 涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失 承擔任何責任。 Beijing Biostar Pharmaceuticals Co., Ltd. 北 京 華 昊 中 天 生 物 醫 藥 股 份 有 限 公 司 本公司謹此就大信國際（ 香港 ）會計師事務所有限公司（「大信」）辭任本公司核數師之原因提 供補充資料。 誠如該公告所披露，本公司變更2025財政年度之核數師乃由於本公司決定將編製財務報表 的基準由香港財務報告準則會計準則更改為中國企業會計準則（「中國企業會計準則」（）「變 更」）。鑒於此會計準則變動，本公司董事會（「董事會」）認為不續聘大信為2025財 ...

格隆汇8月14日丨华昊中天医药-B(02563.HK)宣布，本公司将于2025年8月28日（星期四）举行董事会会 议，藉以（其中包括）(i)考虑及酌情批准本公司及其附属公司截至2025年6月30日止六个月的综合中期 业绩及其刊发；(ii)考虑派付中期股息建议（如有）；及(iii)处理任何其他事项。 ...